KASTEN, INC.

INFORMATION AND DISCLOSURE STATEMENT

FOR THE QUARTER ENDED SEPTEMBER 30, 2016

1) Name of the issuer and its predecessors (if any)

Kasten, Inc.

Formerly known as Geo Vision International Group until October 2013 and as Demco until January 1995.

2) Address of the issuer's principal executive offices

Mailing Address:
Kasten, Inc.
8465 W. Sahara Ave. Suite 111-163
Las Vegas, NV 89117

Website: http://www.kastenbiopharma.com
Phone: 702-860-2407
Email: pr@kastenbiopharma.com

IR Contact

None

3) Security Information

Trading Symbol:
KAST

Exact title and class of securities outstanding:

Common
CUSIP: 48583U107
Par or Stated Value: $0.0001
Common shares authorized: -------- 950,000,000 as of November 10, 2016
Total shares outstanding ---------- 127,501,211 as of November 10, 2016
Total Shareholders: 41 as of November 10, 2016

Transfer Agent

Madison Stock Transfer Inc.
PO Box 145
Brooklyn, NY 11229-0145
718-627-4453

Is the Transfer Agent registered under the Exchange Act? Yes

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months. List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On October 15, 2013, FINRA declared effective a reverse split of the Company's common stock by 1 for 300. In addition, the Company changed its name to Kasten, Inc. and symbol to KAST.

As of November 11, 2016, there were no trading suspensions, stock splits, dividends, recapitalizations, etc.

4) Issuance History Control shares (10% or more)

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);
The shares issued by the Company were issued in accordance with the Securities & Exchange Act section 4(2).

Per the Written Consent of the Board of Directors dated April 25, 2014, the Company was authorized to issue from treasury a total of 50,000,000 new restricted shares of common stock to Prancer Inc. per the terms and conditions of the Product Marketing Agreement.

Per the Written Consent of the Board of Directors dated September 1, 2014, the Company was authorized to issue from treasury a total of 57,000,000 new restricted shares of common stock to TAG Media per the terms and conditions of the Acquisition Agreement of 3IPPPA, an online freelancing marketplace.

B. Any jurisdictions where the offering was registered or qualified;
None

C. The number of shares offered;

D. The number of shares sold;

E. The price at which the shares were offered,

N/A

F. The trading status of the shares;
Restricted, Affiliate Shares. See Control Persons in Section 8 below.

G. The certificates evidencing the shares contain a legend stating that the shares have not been registered under the Securities Act and set forth the restrictions on transferability and sale of the shares under the Securities Act. Officers, directors and control shares are restricted from sale and bear a legend setting forth the restrictions on transferability.

5) Financial Statements

The Company's unaudited financial statements are posted to the OTC Disclosure &News Service as a separate report. They were prepared in accordance with GAAP requirements by the Company's CEO, Jose Delgado. Mr. Delgado has served as an accounting professional for other Companies prior to Kasten, Inc. and has sufficient knowledge to prepare the financials.

6) Describe the Issuer's Business, Products and Services

A. Date and State (or Jurisdiction) of Incorporation:
The issuer was incorporated in 1986 as a Nevada corporation.

B. The issuer's primary and secondary SIC Codes;
Primary SIC Code 2834 Pharmaceutical Preparations

C. The issuer's fiscal year end date;
December 31

D. Principal products or services, and their markets;

Kasten, Inc. has refocused its business operations, and is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings. We are principally focused on delivering solutions to those wards in which the care pathway is burdened by high morbidity, mortality, and cost. Our initial goal is to market the first-in-class *in situ* product for the prevention of surgical site infections in abdominal surgeries.

Appointment of Michael Handley
as Executive Chairman

On August 23, 2016, Michael K. Handley, was appointed Executive Chairman of the Board to help facilitate this new direction. Mr. Handley is a successful life science executive responsible for 17 product approvals and commercial launches. Currently, he serves as Chief Executive Officer and Director of CHD Bioscience Inc. Previously, he was Senior VP at Vessix Vascular (sold to BSX for $435M); Global Head, Regulatory Affairs and Product Integration at Acclarent (acquired by J&J for $785M) and Chief Compliance Officer and VP of global regulatory affairs at Spectranetics Corporation.

Exclusive Sublicense Agreement

On November 7, 2016, the Company entered into an Exclusive Sublicense Agreement with a private corporation, which holds the license to International PCT Patent Application No. PCT/CA 2016/000230, under a Master License Agreement with the Governors of the University of Alberta ("UA").

Description of the Intellectual Property Licensed by the Company

The licensed IP represents an opportunity for use in prescription and over-the-counter antibiotic ointments and eyedrops.

Staphylococcus aureus is the most common causative agent for skin infections in both humans and animals. In particular, methicillin-resistant S. aureus (MRSA) poses a serious threat to public health systems. Present over-the-counter antibiotic ointments, which often contain bacitracin as an active antimicrobial ingredient, are not effective against hyper-resistant MRSA strains, such as USA300. These strains are in fact highly prevalent in the community and current antibiotic ointments may not kill and actually enrich the population of hyper-resistant S. aureus. New strategies are needed to control emerging resistant pathogenic bacteria.

Dr. Byeonghwa Jeon from the University of Alberta has developed an innovative, easy-to-apply antimicrobial formulation that significantly potentiates the activity of bacitracin by using alkyl gallates, a group of antioxidants that are currently utilized as food preservatives. The combination of bacitracin with particular alkyl gallates resulted in up to 1,000,000-fold increase in bactericidal activity against hyper-resistant MRSA strain USA300 and other multidrug-resistant human clinical isolates. The spectrum of antimicrobial activity against other various pathogens is currently being characterized by Dr. Jeon.

Term Sheet with Large Multi-national Pharmaceutical Company

On November 8, 2016, the Company entered into a Non Binding Term Sheet with a large multi-national pharmaceutical company. The Term Sheet allows the Company

exclusivity until December 15, 2016 to negotiate a definitive written license agreement pursuant to which the Company will license certain intellectual property, including patents and patent applications related to a late-stage clinical drug asset used to mitigate surgical site infections.

3IPPA

Prior to the Company's decision to focus on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings, the Company operated 3IPPA.com.

With its acquisition of 3IPPA on September 1, 2014 , the Company became an online freelancing and outsourcing marketplace. It connects employers and freelancers globally. It was described as the only time based freelancer website where work price is dependent on the time of the programmer. In addition, unlike other freelance companies, it is not limited to workplace projects but allows anyone to find the right person for the right job. With experts from around the world showcasing their talents, 3IPPA provides the platform to get help instantly. The Company is exploring opportunities for the sale of 3IPPA.com, in order to focus all of its time and resources on growing its new business model.

Kasten Mobile

Prior to the acquisition of 3IPPA, the Company launched Kasten Mobile which was a mobile app development company. Due to heavy competition and the landscape of the mobile app marketplace, the Company decided it was in its best to focus its resources exclusively on the 3IPPA opportunity.

7) Describe the Issuer's Facilities

The Company is researching available office space for lease on the East Coast for the development and commercialization of pharmaceutical assets. At the present time, the Officers and Directors provide the Company with office space on a month to month basis at no cost.

8) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

Officers and Directors

Jose Delgado, Chief Executive Officer and Director

Michael Handley, Executive Chairman

Control Persons

Prancer Inc – 50,000,000 Shares of Common Stock, 39.215%
beneficially owned by Robert Rockwell

Tag Media Holdings, Inc. – 57,000,000 Shares of Common Stock, 44.705%
beneficially owned by Michael Jacobs

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.
None

C. Beneficial Shareholders of Greater than Five Percent (5%)

Prancer Inc – 50,000,000 Shares of Common Stock, 39.215%
Robert Rockwell
1 Mapp Street
Belize City, Belize

Tag Media Holdings, Inc. – 57,000,000 Shares of Common Stock, 44.705%

Michael Jacobs
1712 Pioneer Ave Suite 1748
Cheyenne, WY 82001

9) Third Party Providers

1. Investment Banker: None

2. Promoters: None

3. Legal Counsel:

Matheau J.W. Stout, Esq.
400 East Pratt Street
8th Floor
Baltimore, MD 21202
(410) 429-7076
mstout@otclawyers.com

4. Accountants or Auditor: None - The Company's financial statements are currently prepared internally; they are not reviewed or audited.

5. Public Relations Consultant(s): None

6. Investor Relations Consultant: None

10) Issuer Certification

I, Jose Delgado, certify that:

I have reviewed this Quarterly Disclosure Statement of Kasten, Inc. and based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 14, 2016

/s/ Jose Delgado
CEO